Press releases

Varian Expects to Benefit from the Extension of Medical Linear Accelerators Tariff Exclusion in China

Varian (NYSE: VAR) has received notice from the Customs Tariff Commission of the State Council of China that the first exclusion of the additional tariffs China imposed on US products will expire...

Varian Drives Next Evolution of Proton Treatment Planning with Eclipse v16.1

Highlights: Integration of Dual Energy CT (DECT) images in the Eclipse planning process reduces range uncertainty and helps clinicians' spare healthy tissue. Graphics Processing Unit (GPU)...

Varian Announces Appointment of Chris Toth as President and Chief Operating Officer

Varian (NYSE: VAR) today announced the following leadership appointments, effective October 5, 2020: Chris Toth, Varian Oncology Systems President, has been appointed to the newly created role of...

Blog posts

HyperArc Proves Itself in Study after Study: A Brief Survey of Recent Literature

Centerline

When a new treatment technology comes on the scene, clinicians naturally want to be assured that it meets or exceeds the performance of established and familiar ones. Since HyperArc® high-definition radiotherapy was introduced at ASTRO in 2016, at least 8...

Read more

HyperArc Helps Community-Based Hospital Radiosurgery Program Succeed in a Highly Competitive Market

Centerline

Varian’s HyperArc® high-definition radiosurgery, delivered on the Edge® platform, is helping the radiosurgery program at Good Samaritan, a 408-bed community hospital in West Islip, NY, succeed in the highly competitive New York City (NYC) area market.

Read more

Is Prostate SBRT a Valid Option? The Evidence is In, and It's Good News

Centerline

After decades of data collected on thousands of patients, evidence points to SBRT as a safe and effective option for the treatment of early- to mid-stage prostate cancer.

Read more

Image Gallery

Brachytherapy Treatment Planning Systems
Clinac® iX medical linear accelerator, rotating
Ethos™ therapy
Ethos™ therapy